Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.62 |
| ▸ | NOS1 | P29475 | 5/20 | 0.52 |
| ▸ | METAP2 | P50579 | 3/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722064 | 0.94 | AXL (0.56) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| Hydrochloric Acid SCHEMBL28618072 | 0.92 | AXL (0.54) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL29769140 | 0.82 | CHEK1 (0.58) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL8404434 | 0.82 | CHEK1 (0.58) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL1273919 | 0.79 | CHEK1 (0.73) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL18554004 | 0.78 | AXL (0.56) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| Hydrochloric Acid SCHEMBL15640013 | 0.78 | CHEK1 (0.70) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL828690 | 0.78 | AXL (0.56) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL22655868 | 0.78 | AXL (0.56) | AXLNOS1METAP2DYRK1ACSNK2A1 | |
| SCHEMBL18290048 | 0.78 | AXL (0.56) | AXLNOS1METAP2DYRK1ACSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20250214971-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-07-03 | — | — | US | disclosed |
| CN-116113627-B | Ji Yin-dole glucocorticoid receptor antagonists | 科赛普特治疗公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-04-10 | — | — | US | disclosed |
| US-20250092023-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-03-20 | — | — | US | disclosed |
| US-12180186-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-12-31 | — | — | US | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-4452968-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | Corcept Therapeutics Incorporated (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118715217-A | Piperazine indole glucocorticoid receptor antagonists | 科赛普特治疗公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12098141-B2 | Bicyclic indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-09-24 | — | — | US | disclosed |
| US-20110112299-A1 | TETRACYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2308880-A1 | TETRACYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7919514-B2 | Protein kinase B inhibitors; anticarcinogenic, antiinflammatory and antiproliferative agents; metabolic disorders; 3-(3-fluoro-phenyl)-N-[5-(3-methyl-1H-indazol-5-yl)-[1,3,4]thiadiazol-2-yl]-propane-1,2-diamine and derivatives | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7700636-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1809282-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | AMGEN INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2006044860-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | AXL 4385/4885NOS1 3026/4885METAP2 3622/4885 |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | AXL 2597/4885NOS1 1566/4885METAP2 2686/4885 |
| US-20250092023-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR5A2 | AXL 4572/4885NOS1 3147/4885METAP2 4220/4885 |
| US-12180186-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | AXL 3356/4885NOS1 4171/4885METAP2 4030/4885 |
| US-12098141-B2 | Bicyclic indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, NR1I2 | AXL 4385/4885NOS1 3026/4885METAP2 3622/4885 |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | AXL 2597/4885NOS1 1566/4885METAP2 2686/4885 |
| US-20250214971-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | AXL 3356/4885NOS1 4171/4885METAP2 4030/4885 |
| US-20110112299-A1 | TETRACYCLIC COMPOUND | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, LPXN | AXL 1385/4885NOS1 2639/4885METAP2 3683/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | AXL 1123/4885NOS1 4532/4885METAP2 1015/4885 |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | AXL 2597/4885NOS1 1566/4885METAP2 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.